Literature DB >> 19252794

In vivo mapping of incremental cortical atrophy from incipient to overt Alzheimer's disease.

Giovanni B Frisoni1, Annapaola Prestia, Paul E Rasser, Matteo Bonetti, Paul M Thompson.   

Abstract

Progressive brain atrophy is believed to be the Alzheimer's disease (AD) marker with the greatest evidence for validity. Mapping the topography of cortical atrophy throughout the stages of severity may allow the neural networks affected to be identified. Twenty healthy elderly persons (OH, MMSE 29.1 +/- 1.0), 11 patients with incipient AD (iAD, 26.5 +/- 2.0), 15 with mild AD (miAD, 23.5 +/- 2.2), and 15 with moderate AD (moAD, 16.5 +/- 2.0) underwent 3D magnetic resonance. Cortical pattern matching analysis was performed and maps of percent differences in gray matter distribution were computed between the following groups: iAD versus OH, miAD versus iAD, and moAD versus miAD. Compared to OH, iAD patients exhibited a mean cortical gray matter loss of 9-20% in areas encompassing the polysynaptic hippocampal pathway (posterior cingulate/retrosplenial and medial temporal cortex) and subgenual/orbitofrontal cortices, and a less widespread loss of 5-11% in other neocortical areas. Compared to iAD, miAD featured widespread mean gray matter loss of 14-19% in areas encompassing the direct hippocampal pathway (temporal pole, temporoparietal association cortex, and dorsal prefrontal cortex), sensorimotor, and visual cortex, with a less marked loss (7-9%) in the polysynaptic pathway areas. Compared to miAD, only atrophy in the primary sensorimotor cortex was still relatively marked in moAD, with a mean gray matter loss of 10-11%; the loss in other regions was generally below 10%. These findings suggest that the polysynaptic hippocampal pathway is affected in iAD, the direct pathway and sensorimotor and visual networks are affected in moAD, and the sensorimotor network is affected in moAD.

Entities:  

Mesh:

Year:  2009        PMID: 19252794     DOI: 10.1007/s00415-009-5040-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  39 in total

1.  Functional MR imaging during odor stimulation: preliminary data.

Authors:  D M Yousem; S C Williams; R O Howard; C Andrew; A Simmons; M Allin; R J Geckle; D Suskind; E T Bullmore; M J Brammer; R L Doty
Journal:  Radiology       Date:  1997-09       Impact factor: 11.105

2.  Evaluation of the motor cortex by magnetic stimulation in patients with Alzheimer disease.

Authors:  A Perretti; D Grossi; N Fragassi; B Lanzillo; M Nolano; A I Pisacreta; G Caruso; L Santoro
Journal:  J Neurol Sci       Date:  1996-01       Impact factor: 3.181

3.  Validation study of the three-objects-three-places test: a screening test for Alzheimer's disease.

Authors:  Annapaola Prestia; Roberta Rossi; Cristina Geroldi; Samantha Galluzzi; Monica Ettori; Giuseppina Alaimo; Giovanni B Frisoni
Journal:  Exp Aging Res       Date:  2006 Oct-Dec       Impact factor: 1.645

4.  Primary motor cortex involvement in Alzheimer disease.

Authors:  D Suvà; I Favre; R Kraftsik; M Esteban; A Lobrinus; J Miklossy
Journal:  J Neuropathol Exp Neurol       Date:  1999-11       Impact factor: 3.685

5.  Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study.

Authors:  G Chételat; B Landeau; F Eustache; F Mézenge; F Viader; V de la Sayette; B Desgranges; J-C Baron
Journal:  Neuroimage       Date:  2005-10-01       Impact factor: 6.556

6.  Imaging the progression of Alzheimer pathology through the brain.

Authors:  A David Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

7.  The topography of grey matter involvement in early and late onset Alzheimer's disease.

Authors:  Giovanni B Frisoni; Michela Pievani; Cristina Testa; Francesca Sabattoli; Lorena Bresciani; Matteo Bonetti; Alberto Beltramello; Kiralee M Hayashi; Arthur W Toga; Paul M Thompson
Journal:  Brain       Date:  2007-02-09       Impact factor: 13.501

8.  Motor cortex excitability in Alzheimer's disease: a transcranial magnetic stimulation study.

Authors:  Florinda Ferreri; Flavia Pauri; Patrizio Pasqualetti; Rita Fini; Gloria Dal Forno; Paolo Maria Rossini
Journal:  Ann Neurol       Date:  2003-01       Impact factor: 10.422

9.  Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

Authors:  N C Fox; R S Black; S Gilman; M N Rossor; S G Griffith; L Jenkins; M Koller
Journal:  Neurology       Date:  2005-05-10       Impact factor: 9.910

10.  Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI.

Authors:  Rachael I Scahill; Jonathan M Schott; John M Stevens; Martin N Rossor; Nick C Fox
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

View more
  51 in total

1.  Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features.

Authors:  Yang Li; Yaping Wang; Guorong Wu; Feng Shi; Luping Zhou; Weili Lin; Dinggang Shen
Journal:  Neurobiol Aging       Date:  2011-01-26       Impact factor: 4.673

2.  Mapping the structural brain changes in Alzheimer's disease: the independent contribution of two imaging modalities.

Authors:  Elisa Canu; Donald G McLaren; Michele E Fitzgerald; Barbara B Bendlin; Giada Zoccatelli; Franco Alessandrini; Francesca B Pizzini; Giuseppe K Ricciardi; Alberto Beltramello; Sterling C Johnson; Giovanni B Frisoni
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects.

Authors:  Xue Hua; Alex D Leow; Neelroop Parikshak; Suh Lee; Ming-Chang Chiang; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2008-07-22       Impact factor: 6.556

4.  Microstructural diffusion changes are independent of macrostructural volume loss in moderate to severe Alzheimer's disease.

Authors:  Elisa Canu; Donald G McLaren; Michele E Fitzgerald; Barbara B Bendlin; Giada Zoccatelli; Franco Alessandrini; Francesca B Pizzini; Giuseppe K Ricciardi; Alberto Beltramello; Sterling C Johnson; Giovanni B Frisoni
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 5.  The clinical use of structural MRI in Alzheimer disease.

Authors:  Giovanni B Frisoni; Nick C Fox; Clifford R Jack; Philip Scheltens; Paul M Thompson
Journal:  Nat Rev Neurol       Date:  2010-02       Impact factor: 42.937

6.  Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease.

Authors:  Claudio Babiloni; Claudio Del Percio; Marina Boccardi; Roberta Lizio; Susanna Lopez; Filippo Carducci; Nicola Marzano; Andrea Soricelli; Raffaele Ferri; Antonio Ivano Triggiani; Annapaola Prestia; Serenella Salinari; Paul E Rasser; Erol Basar; Francesco Famà; Flavio Nobili; Görsev Yener; Derya Durusu Emek-Savaş; Loreto Gesualdo; Ciro Mundi; Paul M Thompson; Paolo M Rossini; Giovanni B Frisoni
Journal:  Neurobiol Aging       Date:  2014-09-21       Impact factor: 4.673

Review 7.  Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.

Authors:  A Del Sole; S Malaspina; Alberto Magenta Biasina
Journal:  Funct Neurol       Date:  2016 Oct/Dec

8.  Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans.

Authors:  Xue Hua; Derrek P Hibar; Suh Lee; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2010-08       Impact factor: 4.673

9.  Atrophy and lower regional perfusion of temporo-parietal brain areas are correlated with impairment in memory performances and increase of EEG upper alpha power in prodromal Alzheimer's disease.

Authors:  Vito Davide Moretti
Journal:  Am J Neurodegener Dis       Date:  2015-09-10

10.  rTMS for the treatment of Alzheimer's disease: where should we be stimulating?

Authors:  Alesha Heath; J L Taylor; M Windy McNerney
Journal:  Expert Rev Neurother       Date:  2018-10-29       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.